OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).
OBM Neurobiology publishes research articles, technical reports and invited topical reviews. Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 11.8 days from acceptance to publication (median values for papers published in this journal in the second half of 2021, 1-2 days of FREE language polishing time is also included in this period).
Emerging Treatments for Mood Disorders
Submission Deadline: July 31, 2022 (Open) Submit Now
Trevor Norman, PhD, Associate Professor
Department of Psychiatry, Austin Hospital, University of Melbourne, Heidelberg, Victoria, Australia
Research interests: Psychopharmacology, Depression, Anxiety Disorders, Stress, Cognition, Circadian rhythms, Animal models, Pharmacokinetics
About this Topic
The middle of the twentieth century saw the introduction of medications for the treatment of major psychiatric disorders ushering in a new optimism for the field and the birth of a new discipline of psychopharmacology. Subsequent years have recognised the many shortcomings of the medications developed at that time and in the intervening period. Most recently there has been a relative dearth of new psychopharmacological agents emanating from the pharmaceutical industry. Nevertheless, there continues to be innovations in the treatment of mood disorders, from the use of agents deriving from insights into the structure and function of receptors to the use of psychedelic agents as adjuncts to psychotherapy. This issue critically examines some of these innovations with a view to placing them in the context of ongoing pharmacotherapeutic practice.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.